Skip to main content
EJNMMI Radiopharmacy and Chemistry

Table 6 A summary of GRPR targeted radiopharmaceuticals and their serum stabilities, tumour-to-blood (T:B) and tumour-to-muscle (T:M) ratios at a given time point post-injection

From: The aluminium-[18F]fluoride revolution: simple radiochemistry with a big impact for radiolabelled biomolecules

[18F]AlF radioconjugate

Serum stability at 1 h (%)a

T:B ratio

T:M ratio

Time point p.i. (h)b

References

[18F]AlF-NODAGA-RM1

> 90

10.29

14.58

2

Liu et al. (2013)

[18F]AlF-NODAGA-AMBA

72.5

–

8c

2

Liu et al. (2013)

[18F]AlF-NOTA-8-Aoc-BBN(7–14)NH2

–

49.51

–

1

Dijkgraaf et al. (2012)

[18F]AlF-NOTA-4,7-lanthionine-BBN

> 80 (human serum)

0.71

9.11

2

Carlucci et al. (2015)

[18F]AlF-NOTA-2,6-lanthionine-BBN

> 80 (human serum)

1.24

6.7

2

Carlucci et al. (2015)

[18F]AlF-NOTA(6)-MATBBN

> 95 (human serum)

9.44

30.70

1

Pan et al. (2014)

[18F]AlF-JMV5132

–

106

305c

1

Chatalic et al. (2014)

[18F]AlF-NOTA-P2-RM26

> 98

87

159

3

Varasteh et al. (2013)

  1. aIntact parent radioconjugate in mouse serum after 1 h incubation, unless stated otherwise
  2. bThe timepoint post-injection where T:B and T:M data is reported. T:B = tumour-to-blood ratio and T:M = tumour-to-muscle ratio calculated from ex vivo biodistribution data presented in the original manuscript and represented as a mean value
  3. cEstimated from graphical data in the original manuscript
Back to article page